This work is licensed under a
Creative Commons Attribution 4.0 International License
 J.Y. Mabrut, J.M. Collard, J. Baulieux, Duodenogastric and gastroesophageal bile reflux, J. Chir. 143(6) (2006) 355-365.
 A. Agrawal et al., Symptoms with acid and nonacid reflux may be produced by different mechanisms, Dis. Esophagus. 22 (2009) 467–470.
 G. Boeckxstaens et al., Symptomatic reflux disease: the present, the past and the future, Gut. 63(7) (2014) 1185–1193.
 S. Jürgens et al., The role of bile acids in the neoplastic progression of Barrett's esophagus - a short representative overview, Z. Gastroenterol. 50 (2012) 1028-1034.
 F. Hvid-Jensen et al., Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med. 365 (2011) 1375–1383.
 K.R. McQuaid et al., Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia, Aliment. Pharmacol. Ther. 34(2) (2011) 146-165.
 Y.J. Kim, E.H. Kim, K.B. Hahm, Oxidative stress in inflammation-based gastrointestinal tract diseases: challenges and opportunities, J. Gastroenterol. Hepatol. 27 (2012) 1004-1010.
 K. Dvorak et al., Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus, Gut. 56 (2007) 763–771.DOI: 10.1136/gut.2006.103697
 A.J. Jolly, C.P. Wild, L.J. Hardie. Sodium deoxycholate causes nitric oxide mediated DNA damage in oesophageal cells, Free Radic. Res. 43 (2009) 234–240.DOI: 10.1080/10715760802684211
 J. Theisen et al., The mutagenic potential of duodenoesophageal reflux, Ann Surg. 241 (2005) 63–68.
 R. Zhang et al., Bile salts inhibit growth and induce apoptosis of culture human normal esophageal mucosal epithelial cells, World J. Gastroenterol. 11 (2005) 6466–6471.
 K. Dvorakova et al., Apoptosis resistance in Barrett's esophagus: ex vivo bioassay of live stressed tissues, Am. J. Gastroenterol. 100 (2005) 424–431.
 T.K. Desai et al., The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis, Gut. 61 (2012) 970–976.
 A. Nakos et al., The histological and immunohistochemical aspects of bile reflux in patients with gastroesophageal reflux disease, Gastroenterol. Res. Pract. 2011 (2011) 1-9.
 P.J. Kahrilas, N.J. Shaheen, M.F. Vaezi, American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease, Gastroenterol. 135 (2008) 1392-1413.
 D.A. Johnson, B.H. Levy, 3rd Evolving drugs in gastroesophageal reflux disease: pharmacologic treatment beyond proton pump inhibitors, Expert Opinion on Pharmacotherapy. 11(9) (2010) 1541–1548.
 J. Venkataraman, A. Krishnan, Long-term medical management of gastro-esophageal reflux disease: how long and when to consider surgery?, Trop. Gastroenterol. 33(1) (2012) 21-32.
 S.M. Wilhelm, R.G. Rjater, P.B. Kale-Pradhan, Perils and pitfalls of long-term effects of proton pump inhibitors, Expert Rev. Clin. Pharmacol. 6 (2013) 443-451.
 Mas R. D-002: A product obtained from beeswax, Drugs of the Future. 26 (2001) 731-744.
 D. Carbajal et al., Anti-ulcer activity of higher primary alcohols of beeswax, J. Pharm. Pharmacol. 47 (1995) 731-733.
 D. Carbajal et al., Possible cytoprotective mechanism in rats of D-002 an anti-ulcerogenic product isolated from beeswax, J. Pharm. Pharmacol. 48 (1996) 858-860.
 D. Carbajal et al., Effects of D-002 on gastric mucus composition in ethanol-induced ulcer, Pharmacol. Res. 42 (2000) 329-332.
 V. Molina et al., Antioxidant effects of D-002 on gastric mucosa of rats with experimentally-induced injury, J. Med. Food. 4 (2001) 79-83.
 Y. Pérez et al., Protective effect of D-002, a mixture of beeswax alcohols, against indomethacin-induced gastric ulcers and mechanism of action, J. Nat. Med. 67 (2013) 182-189.
 Y. Pérez et al., Inhibition of cyclooxygenase and 5-lipooxygenase enzymes by D-002 (beeswax alcohols). Current Topics in Nutraceuticals Research. 12(1/2) (2014) 13-18.
 M. Okazaki et al., Gastric mucosal levels of prostaglandins and leukotrienes in patients with gastric ulcer after treatment with rabeprazole in comparison to treatment with ranitidine, J. Med. Invest. 54 (2007) 83-90.
 Z. Zamora et al., Protective effects of D-002 on experimentally induced gastroesophageal reflux in rats, World J. Gastroenterol. 20 (2014) 2085-(2090).
 Z. Zamora et al., Effects of D-002 on esophagitis induced by duodenal- esophageal reflux (DER) and duodenogastro-esophageal reflux (DGER) in rats, Int. J. of Pharmacol. Toxicol. 5(3) (2015) 146-151.
 N. Inatomi et al., Effects of a proton pump inhibitor, AG-1749 (Lanzoprazole), on reflux esophagitis and experimental ulcers in rats, Japan J. Pharmacol. 55 (1991) 437-451.
 N. Hashimoto, Expression of COX2 and p.53 in rat esophageal cancer induced by reflux of duodenal contents, ISRN Gastroenterol. 2012 (2012) 1-5.
 Y. Li, R.C. Martin, 2nd Reflux injury of esophageal mucosa: experimental studies in animal models of esophagitis, Barrett's esophagus and esophageal adenocarcinoma, Dis. Esophagus. 20 (2007) 372–378.
 H. Aiyer, L. Yan, R. Martin, Diet composition affects surgery-associated weight loss in rats with a compromised alimentary tract, J. Surg. Res. 168 (2011) 42–48.
 H.S. Aiyer et al., Dietary freeze dried black raspberry's effect on cellular antioxidant status during reflux-induced esophagitis in rats, Nutrition. 27 (2011) 182–187.
 D. Asaoka et al., Characteristic pathological findings and effects of ecabet sodium in rat reflux esophagitis, World J. Gastroenterol. 15(28) (2009) 3480–3485.
 R.R. Kedika, R.F. Souza, S.J. Spechler, Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications, Digestive diseases and sciences. 54(11) (2009) 2312–2317.
 T.Y. Oh et al., Oxidative damages are critical in pathogenesis of reflux esophagitis: implication of antioxidants in its treatment, Free Radic Biol Med. 30 (2001) 905-915.